Intra-articular MSC injections in RA patients have reduced synovial inflammation and cartilage degradation, correlating with diminished NK cell activity and IL-6 levels in synovial fluid (Augello et al., 2007; Papadopoulou et al., 2012). Here, IL6 is linked to rheumatoid arthritis.